Trial Profile
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of VX-770 to Evaluate Safety, Pharmacokinetics, and Biomarkers of CFTR Activity in Cystic Fibrosis (CF) Subjects With Genotype G551D
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Biomarker
- Sponsors Vertex Pharmaceuticals
- 28 Oct 2013 New trial record